ReviewBioMed research international2013
Translational bioinformatics for diagnostic and prognostic prediction of prostate cancer in the next-generation sequencing era.
Review in BioMed research international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Androgen deprivation therapy use and the risk of heart failure in patients with prostate cancer: a systematic review and meta-analysis.BMC cardiovascular disorders · 2024Pooled it
- ASF1A: A versatile histone chaperone bridging chromatin dynamics, disease mechanisms and clinical potential (Review).Experimental and therapeutic medicine · 2026Review
- New Users of Sodium-Glucose Cotransporter 2 Inhibitors Are at Low Risk of Prostate Cancer: A Nationwide Cohort Study.Diabetes & metabolism journal · 2026Article
- PSMA-targeted radioligand therapy in advanced prostate cancer: a narrative review of ^177Lu-PSMA, emerging ^225Ac-PSMA strategies, and therapeutic sequencing.Oncology reviews · 2026Review
- Influence of high-performance image-to-image translation networks on clinical visual assessment and outcome prediction: utilizing ultrasound to MRI translation in prostate cancer.International journal of computer assisted radiology and surgery · 2026Article
- Research Advances in Cancer-Associated Fibroblasts in Prostate Cancer Progression.Biomolecules · 2025Review
- Synchronous/Metachronous Prostate Cancer with Other Cancer Sites-The Experience of a Single Center in Romania.Medicina (Kaunas, Lithuania) · 2025Article
- A branching bivariate weibull distribution model for evaluating exosomes in androgen-deprived agency in the presence of prostate cancer.Scientific reports · 2025Article
- Review
- Article
- Real-Time and Ultrasensitive Prostate-Specific Antigen Sensing Using Love-Mode Surface Acoustic Wave Immunosensor Based on MoSSensors (Basel, Switzerland) · 2024Article
- Detecting Clinically Significant Prostate Cancer in PI-RADS 3 Lesions Using T2w-Derived Radiomics Feature Maps in 3T Prostate MRI.Current oncology (Toronto, Ont.) · 2024Article
- MicroRNAs as Promising Therapeutic Agents Against Prostate Cancer Resistant to Castration-Where Are We Now?Pharmaceutics · 2024Review
- In silico exploration of anti-prostate cancer compounds from differential expressed genes.BMC urology · 2024Article
- Biological functions and therapeutic potential of CKS2 in human cancer.Frontiers in oncology · 2024Review
- Biological functions and therapeutic potential of SRY related high mobility group box 5 in human cancer.Frontiers in oncology · 2024Review
- Orexins and Prostate Cancer: State of the Art and Potential Experimental and Therapeutic Perspectives.Cancer genomics & proteomics · 2023Review
- Role of Mangiferin in Management of Cancers through Modulation of Signal Transduction Pathways.Biomedicines · 2023Review
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discovery of prostate cancer biomarkers has been boosted by the advent of next-generation sequencing (NGS) technologies. Nevertheless, many challenges still exist in exploiting the flood of sequence data and translating them into routine diagnostics and prognosis of prostate cancer. Here we review the recent developments in prostate cancer biomarkers by high throughput sequencing technologies. We highlight some fundamental issues of translational bioinformatics and the potential use of cloud computing in NGS data processing for the improvement of prostate cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.